VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung

R. T. Eagan, J. N. Ingle, E. T. Creagan, S. Frytak, L. K. Kvols, J. Rubin, R. T. McMachon

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

VP-16-213 is a semisynthetic podophyllotoxin derivative which has been observed to have considerable activity against small cell undifferentiated lung cancer. Based on that encouraging clinical finding and the fact that the drug in the oral form has shown some activity against adenocarcinoma (ACA) of the lung as well, we elected to further evaluate the drug in patients with advanced squamous cell carcinoma (SQC) and ACA of the lung. VP-16-213 is a relatively well-tolerated chemotherapeutic agent when used in the manner described in this study. Definite antitumor activity was demonstrated in patients with both ACA and SQC of the lung. The overall regression rate of 18% (eight of 44 patients) when both ACA and SQC patients were combined, puts the drug in the same activity range as most single agents considered to have some effect in ACA and SQC of the lung such as cyclophosphamide and adriamycin.

Original languageEnglish (US)
Pages (from-to)843-844
Number of pages2
JournalCancer Treatment Reports
Volume62
Issue number5
StatePublished - 1978

Fingerprint

Etoposide
Squamous Cell Carcinoma
Drug Therapy
Adenocarcinoma
Pharmaceutical Preparations
Podophyllotoxin
Lung
Small Cell Lung Carcinoma
Doxorubicin
Cyclophosphamide
Adenocarcinoma of lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Eagan, R. T., Ingle, J. N., Creagan, E. T., Frytak, S., Kvols, L. K., Rubin, J., & McMachon, R. T. (1978). VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. Cancer Treatment Reports, 62(5), 843-844.

VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. / Eagan, R. T.; Ingle, J. N.; Creagan, E. T.; Frytak, S.; Kvols, L. K.; Rubin, J.; McMachon, R. T.

In: Cancer Treatment Reports, Vol. 62, No. 5, 1978, p. 843-844.

Research output: Contribution to journalArticle

Eagan, RT, Ingle, JN, Creagan, ET, Frytak, S, Kvols, LK, Rubin, J & McMachon, RT 1978, 'VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung', Cancer Treatment Reports, vol. 62, no. 5, pp. 843-844.
Eagan RT, Ingle JN, Creagan ET, Frytak S, Kvols LK, Rubin J et al. VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. Cancer Treatment Reports. 1978;62(5):843-844.
Eagan, R. T. ; Ingle, J. N. ; Creagan, E. T. ; Frytak, S. ; Kvols, L. K. ; Rubin, J. ; McMachon, R. T. / VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. In: Cancer Treatment Reports. 1978 ; Vol. 62, No. 5. pp. 843-844.
@article{42f45af707854a528c75de0322545938,
title = "VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung",
abstract = "VP-16-213 is a semisynthetic podophyllotoxin derivative which has been observed to have considerable activity against small cell undifferentiated lung cancer. Based on that encouraging clinical finding and the fact that the drug in the oral form has shown some activity against adenocarcinoma (ACA) of the lung as well, we elected to further evaluate the drug in patients with advanced squamous cell carcinoma (SQC) and ACA of the lung. VP-16-213 is a relatively well-tolerated chemotherapeutic agent when used in the manner described in this study. Definite antitumor activity was demonstrated in patients with both ACA and SQC of the lung. The overall regression rate of 18{\%} (eight of 44 patients) when both ACA and SQC patients were combined, puts the drug in the same activity range as most single agents considered to have some effect in ACA and SQC of the lung such as cyclophosphamide and adriamycin.",
author = "Eagan, {R. T.} and Ingle, {J. N.} and Creagan, {E. T.} and S. Frytak and Kvols, {L. K.} and J. Rubin and McMachon, {R. T.}",
year = "1978",
language = "English (US)",
volume = "62",
pages = "843--844",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung

AU - Eagan, R. T.

AU - Ingle, J. N.

AU - Creagan, E. T.

AU - Frytak, S.

AU - Kvols, L. K.

AU - Rubin, J.

AU - McMachon, R. T.

PY - 1978

Y1 - 1978

N2 - VP-16-213 is a semisynthetic podophyllotoxin derivative which has been observed to have considerable activity against small cell undifferentiated lung cancer. Based on that encouraging clinical finding and the fact that the drug in the oral form has shown some activity against adenocarcinoma (ACA) of the lung as well, we elected to further evaluate the drug in patients with advanced squamous cell carcinoma (SQC) and ACA of the lung. VP-16-213 is a relatively well-tolerated chemotherapeutic agent when used in the manner described in this study. Definite antitumor activity was demonstrated in patients with both ACA and SQC of the lung. The overall regression rate of 18% (eight of 44 patients) when both ACA and SQC patients were combined, puts the drug in the same activity range as most single agents considered to have some effect in ACA and SQC of the lung such as cyclophosphamide and adriamycin.

AB - VP-16-213 is a semisynthetic podophyllotoxin derivative which has been observed to have considerable activity against small cell undifferentiated lung cancer. Based on that encouraging clinical finding and the fact that the drug in the oral form has shown some activity against adenocarcinoma (ACA) of the lung as well, we elected to further evaluate the drug in patients with advanced squamous cell carcinoma (SQC) and ACA of the lung. VP-16-213 is a relatively well-tolerated chemotherapeutic agent when used in the manner described in this study. Definite antitumor activity was demonstrated in patients with both ACA and SQC of the lung. The overall regression rate of 18% (eight of 44 patients) when both ACA and SQC patients were combined, puts the drug in the same activity range as most single agents considered to have some effect in ACA and SQC of the lung such as cyclophosphamide and adriamycin.

UR - http://www.scopus.com/inward/record.url?scp=0018154861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018154861&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 843

EP - 844

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 5

ER -